Tariffs on pharmaceutical companies isn’t just good economic policy — it benefits national security and public health.
The United States is amid a dangerous drug shortage that endangers patients, undermines our health care system and exposes a deep vulnerability to national security. America’s overwhelming reliance on foreign manufacturers for generic drugs is at the center of it.
Break out the Grizzly cooler and fire up the Broilmaster—it’s Liberation Day. In President Trump’s words, April 2 marks the end of the US of A being “ripped off by virtually every country in the world.”
The National Institutes of Health (NIH) is today the main source of new drugs in this country – indeed the world, because America leads in the field. It has a critical importance to America’s health. Less well known is its huge, positive, economic impact.
As the United States looks to compete in these advanced industries, it’s important to remember the two building blocks that undergird them: Steel and aluminum.
Tariffs are an effective tool for boosting domestic production. They stimulate critical domestic investment and increase U.S. manufacturing capacity. It’s past time to abandon the outdated dogma of unregulated free trade — and start focusing on rebuilding American industry to create jobs and ensure long-term economic resilience.
